NASDAQ:LTRN Lantern Pharma - LTRN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.58 +0.07 (+1.55%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.55▼$4.6550-Day Range$4.30▼$6.0852-Week Range$4.05▼$7.92Volume9,652 shsAverage Volume36,620 shsMarket Capitalization$49.74 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lantern Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside140.2% Upside$11.00 Price TargetShort InterestHealthy2.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.54) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector439th out of 995 stocksPharmaceutical Preparations Industry203rd out of 482 stocks 3.5 Analyst's Opinion Consensus RatingLantern Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Lantern Pharma has a forecasted upside of 140.2% from its current price of $4.58.Amount of Analyst CoverageLantern Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.10% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently increased by 0.35%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LTRN. Previous Next 2.6 News and Social Media Coverage News SentimentLantern Pharma has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Lantern Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.00% of the stock of Lantern Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.63% of the stock of Lantern Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lantern Pharma are expected to decrease in the coming year, from ($1.54) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantern Pharma (NASDAQ:LTRN) StockLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call TranscriptMarch 23, 2023 | americanbankingnews.comLantern Pharma (NASDAQ:LTRN) Rating Reiterated by EF Hutton Acquisition Co. IMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 22, 2023 | benzinga.comLantern Pharma Stock (NASDAQ:LTRN), Guidance and ForecastMarch 22, 2023 | americanbankingnews.comLantern Pharma (NASDAQ:LTRN) Posts Earnings Results, Beats Expectations By $0.18 EPSMarch 21, 2023 | finance.yahoo.comLantern Pharma to Present at Upcoming Scientific Conferences and WebinarsMarch 21, 2023 | markets.businessinsider.comEF Hutton Reaffirms Their Buy Rating on Lantern Pharma (LTRN)March 21, 2023 | finance.yahoo.comQ4 2022 Lantern Pharma Inc Earnings CallMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 20, 2023 | finance.yahoo.comLantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational HighlightsMarch 19, 2023 | americanbankingnews.comLantern Pharma (LTRN) Scheduled to Post Earnings on MondayMarch 17, 2023 | benzinga.comLantern Pharma's Earnings: A PreviewMarch 15, 2023 | finance.yahoo.comLantern Pharma to Present at the American Association for Cancer Research (AACR) Annual MeetingMarch 13, 2023 | finance.yahoo.comLantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ETMarch 9, 2023 | finance.yahoo.comLantern Pharma Announces New Data and Development Focus for LP-100 with PARP InhibitorsMarch 8, 2023 | finance.yahoo.comLantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.March 6, 2023 | msn.comLantern forms unit Starlight focused on CNS disorders, brain cancersMarch 6, 2023 | finance.yahoo.comLantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain CancersMarch 2, 2023 | finance.yahoo.comLantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical TrialsMarch 1, 2023 | benzinga.comLantern Pharma Stock (NASDAQ:LTRN), Quotes and News SummaryFebruary 27, 2023 | finance.yahoo.comLantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352February 17, 2023 | benzinga.comEF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price TargetFebruary 15, 2023 | finance.yahoo.comLantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug ConjugatesFebruary 1, 2023 | finance.yahoo.comLTRN: LP-184 & LP-284 in the SpotlightJanuary 28, 2023 | msn.comA Passion for Lifelong Learning is Part of the Culture of Lantern HillJanuary 17, 2023 | finance.yahoo.comLantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023January 5, 2023 | finance.yahoo.comFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell LymphomaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Company Calendar Last Earnings3/20/2023Today3/27/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees14Year Founded2013Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+139.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.62% Return on Assets-22.30% Debt Debt-to-Equity RatioN/A Current Ratio20.99 Quick Ratio19.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book0.72Miscellaneous Outstanding Shares10,860,000Free Float8,360,000Market Cap$49.96 million OptionableNot Optionable Beta0.68 Social Links Key ExecutivesMr. Panna Sharma PH.D. (Age 51)Pres, CEO & Director Comp: $622kMr. David R. Margrave (Age 61)CFO & Sec. Comp: $366kDr. Kishor Gopaldas Bhatia Ph.D. (Age 67)Chief Scientific Officer & Scientific Consultant Comp: $151.93kNicole LeberInvestor Relations Associate, Fin. & Admin. CoordinatorDr. Peter L. Nara D.V.M.M.S., Ph.D., Co-Founder & AdvisorKey CompetitorsBioLineRxNASDAQ:BLRXSpero TherapeuticsNASDAQ:SPROBeyondSpringNASDAQ:BYSIHCW BiologicsNASDAQ:HCWBMagenta TherapeuticsNASDAQ:MGTAView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 15,134 shares on 2/15/2023Ownership: 0.139%Susquehanna International Group LLPSold 33,500 shares on 2/14/2023Ownership: 0.000%CM Management LLCBought 10,000 shares on 2/9/2023Ownership: 0.552%Wolff Wiese Magana LLCSold 3,364 shares on 2/9/2023Ownership: 0.250%UBS Group AGBought 2,841 shares on 2/8/2023Ownership: 0.137%View All Insider TransactionsView All Institutional Transactions LTRN Stock - Frequently Asked Questions Should I buy or sell Lantern Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LTRN shares. View LTRN analyst ratings or view top-rated stocks. What is Lantern Pharma's stock price forecast for 2023? 1 brokerages have issued 1-year price targets for Lantern Pharma's stock. Their LTRN share price forecasts range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 139.1% from the stock's current price. View analysts price targets for LTRN or view top-rated stocks among Wall Street analysts. How have LTRN shares performed in 2023? Lantern Pharma's stock was trading at $6.04 at the start of the year. Since then, LTRN shares have decreased by 23.8% and is now trading at $4.60. View the best growth stocks for 2023 here. When is Lantern Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our LTRN earnings forecast. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 20th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.18. During the same quarter in the previous year, the company earned ($0.31) earnings per share. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), First Trust NASDAQ 100 Equal Weighted Index Fund (QQEW), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK). When did Lantern Pharma IPO? (LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. What is Lantern Pharma's stock symbol? Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN." Who are Lantern Pharma's major shareholders? Lantern Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include CM Management LLC (0.55%), Wolff Wiese Magana LLC (0.25%), Jane Street Group LLC (0.14%), UBS Group AG (0.14%), Lynwood Capital Management Inc. (0.11%) and Susquehanna International Group LLP (0.00%). View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantern Pharma's stock price today? One share of LTRN stock can currently be purchased for approximately $4.60. How much money does Lantern Pharma make? Lantern Pharma (NASDAQ:LTRN) has a market capitalization of $49.96 million. The company earns $-12,360,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. How can I contact Lantern Pharma? Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The official website for the company is www.lanternpharma.com. The company can be reached via phone at 972-277-1136 or via email at info@lanternpharma.com. This page (NASDAQ:LTRN) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.